Animal Models

The Scientist, Nov.15, 1993, page 12) concerning the recent commentary by Frederick K. Goodwin and Adrian R. Morrison (The Scientist, Sept.6, 1993, page 12) is telling. Once again, Barnard cleverly zooms in on grains of truth and uses highly selective data, ignoring completely the vast body of information that does not support his ideological bias. While Barnard comments on anecdotal evidence relating to several cases in which data

Written byJerod Loeb
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

While Barnard comments on anecdotal evidence relating to several cases in which data derived from animal experiments were not applicable to human clinical situations, he completely misses critical points. For example according to the Pharmaceutical Manufacturers Association, each year approximately 5,000 new chemical entities are synthesized. Of these 5,000 new chemical entities, 500 are tested in isolated systems, 250 are tested in animals, five are tested in human clinical studies, and only one is ultimately approved by the Food and Drug Administration. Obviously, the important lesson in these data is the protection afforded to society by these rigorous testing processes. At issue is not what we have failed to learn but rather what we have learned.

We must all beware of pronouncements made by an individual whose scientific acumen is driven by personal philosophy that ignores valid research data.

JEROD M. LOEB American Medical Association 515 N. State Street Chicago, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies